John Macor earned his B.S. degree from the University of Notre Dame in 1982 doing undergraduate research with Professor Marvin Miller (a 2016 inductee of the MEDI HOF) and earned his Ph.D. degree at Princeton University with Professor E. C. Taylor (a 2011 inductee of the MEDI HOF) in 1986. Dr. Macor’s career has spanned five different decades and five different pharmaceutical companies with significant contributions in each of them. He began his career at Pfizer (Groton, CT) in 1986 where he was engaged in a variety of CNS drug discovery efforts, moved to Astra Arcus (Rochester, NY) in 1994 focusing on cholinergic drug discovery, and then moved to Bristol-Myers Squibb in 1997 (Princeton, NJ), starting in cardiovascular and moving to neuroscience in 2001 and immunoscience in 2013. He assumed the role as Executive Director of Neuroscience Discovery Chemistry in 2002 (Wallingford, CT), and he was appointed Executive Director of Immunosciences Discovery Chemistry in 2013 (Lawrenceville, NJ). In October 2016, he accepted the role as Global Head of Integrated Drug Discovery for Sanofi with groups in Paris, Frankfurt and Waltham, MA. In 2022, he moved to Sionna Therapeutics as its Chief Scientific Officer (CSO). In 2025, John assumed the role as Chief Scientific Officer for Nabu Therapeutics, a wholly-owned subsidiary of Babylon Biosciences. John has led more than 25 different teams to successful outcomes, i.e., compounds brought to Development for patients with serious unmet medical needs, culminating thus far in four marketed drugs. John is a co-inventor of Relpax® (eletriptan), an anti-migraine agent (5HT1D¬ receptor agonist) discovered during his time at Pfizer. At BMS, he was also a co-inventor of Nurtec ODT® (rimegepant), an oral CGRP receptor antagonist, and Zavzpret® (zavegepant), an intranasally delivered CGRP receptor antagonist, both for the treatment of migraine. Biohaven developed the drugs, and Pfizer acquired both for $11.6 billion in 2022. Also, while at BMS, he was also a co-inventor of Filspari® (sparsentan, a dual AT1/ETA receptor antagonist). Filspari® (sparsentan) was developed by Travere Therapeutics and received accelerated approval in February 2023 for the treatment of IgA nephropathy. John was a co-inventor of BMS-708163 (avagecestat, a γ-secretase inhibitor for Alzheimer’s Disease) that reached Phase 2. At Astra he was co-inventor of AZD0328, an α7 neuronal nicotinic receptor agonist, which advanced to Phase 2 trials for schizophrenia. Dr. Macor is also a co-inventor of LX9211 (an AAK1 inhibitor for neuropathic pain with positive results in Phase 2). Lastly, John is a co-inventor of a number of immunoscience compounds presently in early-stage clinical trials. Dr. Macor has authored/co-authored more than 220 peer-reviewed publications, is an inventor on 145 granted US patents, has given more than 115 invited lectures, and has over 590 publications, issued US patents, invited lectures, and external meeting presentations. His contributions in the syntheses of heterocyclic compounds, intramolecular 1,2,4-triazine Diels-Alder reactions, indole chemistry, and conformation restriction using heterocycles as bioisosteres in medicinal chemistry are widely cited in the literature. He has participated in, and led teams in neuroscience, cardiovascular, metabolic, oncology, immunology, and rare disease projects, indicative of expansive expertise, creativity and impact in medicinal chemistry and drug discovery. Dr. Macor chaired the 2002 Gordon Research Conference on Medicinal Chemistry and the 2006 Gordon Research Conference on Heterocyclic Compounds. Dr. Macor served as Editor-in-Chief of Annual Reports in Medicinal Chemistry for Volumes 42 – 46 (2006 – 2011). Dr. Macor was awarded the 2009 Scarborough Award in Medicinal Chemistry for medicinal chemistry accomplishments under the age of 50 and was honored as an American Society Fellow in 2011. Dr. Macor served as Chair of the Medicinal Chemistry Division (MEDI) of the American Chemical Society in 2015 and served a total of ten years on the Executive Committee of MEDI in various roles. Dr. Macor was awarded the 2014 Alfred Burger Award in Medicinal Chemistry (a National Award from the American Chemical Society) “to recognize outstanding contributions to research in medicinal chemistry,” and was inducted into the Medicinal Chemistry Hall of Fame in August 2014. He was designated as the 2019 Smissman awardee from the MEDI Division of the ACS “given to a living scientist whose research, teaching or service has had a substantial impact on the intellectual and theoretical development of the field of Medicinal Chemistry.” In 2020, he was awarded the IUPAC-Richter Prize in medicinal chemistry “in recognition of his outstanding creative contributions in the field of medicinal chemistry research on drugs for the treatment of migraine.” In 2026 Dr. Macor received the Patrick Woster Awards for Service to the Division of Medicinal chemistry."